Optimizing Treatment of Schizophrenia Enhancing Affective/Cognitive and Depressive Functioning

David L. Ginsberg, Nina R. Schooler, Peter F. Buckley, Philip D. Harvey, Peter J. Weiden

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Recognition and treatment of schizophrenia has largely focused on positive symptoms of the disorder, such as delusions, hallucinations, and disorganization. However, other important symptoms, such as depression, cognition, and social functioning, have not received comparable attention. Fifty percent of schizophrenic patients suffer from comorbid depression, which is a major risk factor for suicide in this population, while 10% to 25% suffer from comorbid obsessive-compulsive disorder. Cognitive deficits commonly observed in patients with schizophrenia include problems with concentration, attention, and memory, as well as problem-solving and verbal skills. These deficits are observed at early stages of the illness and can predict deficits in functional capabilities, such as occupational and social skills, educational attainment, and the ability to live independently. The severity of such impairments affects all patients in this population, including up to 10% of patients working full time and up to one third of those working part time. In light of the debilitating effects of depression, cognitive impairment, and other aspects of affective functioning on the quality of life of patients with schizophrenia, physicians need to partner with their patients to address these concerns and determine an appropriate treatment regimen. This can be done with simple functional-based cognitive questioning, the use of evidence-based psychosocial practices, and psychoeducation on the many pharmacotherapeutic options. It is recommended that depressive or suicidal symptoms of schizophrenia be treated with an antidepressant or mood stabilizer only if the symptoms have not subsided after treatment of the psychosis with an atypical antipsychotic. Additionally, relative to older medications, atypicals have demonstrated benefit in improving some of the cognitive impairments.

Original languageEnglish (US)
Number of pages1
JournalCNS Spectrums
Volume10
Issue number2
DOIs
StatePublished - Jan 1 2005

Fingerprint

Schizophrenia
Depression
Therapeutics
Aptitude
Delusions
Evidence-Based Practice
Hallucinations
Obsessive-Compulsive Disorder
Psychotic Disorders
Suicide
Cognition
Antidepressive Agents
Antipsychotic Agents
Population
Quality of Life
Physicians
Cognitive Dysfunction

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Ginsberg, D. L., Schooler, N. R., Buckley, P. F., Harvey, P. D., & Weiden, P. J. (2005). Optimizing Treatment of Schizophrenia Enhancing Affective/Cognitive and Depressive Functioning. CNS Spectrums, 10(2). https://doi.org/10.1017/S1092852900019337

Optimizing Treatment of Schizophrenia Enhancing Affective/Cognitive and Depressive Functioning. / Ginsberg, David L.; Schooler, Nina R.; Buckley, Peter F.; Harvey, Philip D.; Weiden, Peter J.

In: CNS Spectrums, Vol. 10, No. 2, 01.01.2005.

Research output: Contribution to journalArticle

Ginsberg, David L. ; Schooler, Nina R. ; Buckley, Peter F. ; Harvey, Philip D. ; Weiden, Peter J. / Optimizing Treatment of Schizophrenia Enhancing Affective/Cognitive and Depressive Functioning. In: CNS Spectrums. 2005 ; Vol. 10, No. 2.
@article{1a80859166344375aeff33a280dc1cf0,
title = "Optimizing Treatment of Schizophrenia Enhancing Affective/Cognitive and Depressive Functioning",
abstract = "Recognition and treatment of schizophrenia has largely focused on positive symptoms of the disorder, such as delusions, hallucinations, and disorganization. However, other important symptoms, such as depression, cognition, and social functioning, have not received comparable attention. Fifty percent of schizophrenic patients suffer from comorbid depression, which is a major risk factor for suicide in this population, while 10{\%} to 25{\%} suffer from comorbid obsessive-compulsive disorder. Cognitive deficits commonly observed in patients with schizophrenia include problems with concentration, attention, and memory, as well as problem-solving and verbal skills. These deficits are observed at early stages of the illness and can predict deficits in functional capabilities, such as occupational and social skills, educational attainment, and the ability to live independently. The severity of such impairments affects all patients in this population, including up to 10{\%} of patients working full time and up to one third of those working part time. In light of the debilitating effects of depression, cognitive impairment, and other aspects of affective functioning on the quality of life of patients with schizophrenia, physicians need to partner with their patients to address these concerns and determine an appropriate treatment regimen. This can be done with simple functional-based cognitive questioning, the use of evidence-based psychosocial practices, and psychoeducation on the many pharmacotherapeutic options. It is recommended that depressive or suicidal symptoms of schizophrenia be treated with an antidepressant or mood stabilizer only if the symptoms have not subsided after treatment of the psychosis with an atypical antipsychotic. Additionally, relative to older medications, atypicals have demonstrated benefit in improving some of the cognitive impairments.",
author = "Ginsberg, {David L.} and Schooler, {Nina R.} and Buckley, {Peter F.} and Harvey, {Philip D.} and Weiden, {Peter J.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1017/S1092852900019337",
language = "English (US)",
volume = "10",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "2",

}

TY - JOUR

T1 - Optimizing Treatment of Schizophrenia Enhancing Affective/Cognitive and Depressive Functioning

AU - Ginsberg, David L.

AU - Schooler, Nina R.

AU - Buckley, Peter F.

AU - Harvey, Philip D.

AU - Weiden, Peter J.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Recognition and treatment of schizophrenia has largely focused on positive symptoms of the disorder, such as delusions, hallucinations, and disorganization. However, other important symptoms, such as depression, cognition, and social functioning, have not received comparable attention. Fifty percent of schizophrenic patients suffer from comorbid depression, which is a major risk factor for suicide in this population, while 10% to 25% suffer from comorbid obsessive-compulsive disorder. Cognitive deficits commonly observed in patients with schizophrenia include problems with concentration, attention, and memory, as well as problem-solving and verbal skills. These deficits are observed at early stages of the illness and can predict deficits in functional capabilities, such as occupational and social skills, educational attainment, and the ability to live independently. The severity of such impairments affects all patients in this population, including up to 10% of patients working full time and up to one third of those working part time. In light of the debilitating effects of depression, cognitive impairment, and other aspects of affective functioning on the quality of life of patients with schizophrenia, physicians need to partner with their patients to address these concerns and determine an appropriate treatment regimen. This can be done with simple functional-based cognitive questioning, the use of evidence-based psychosocial practices, and psychoeducation on the many pharmacotherapeutic options. It is recommended that depressive or suicidal symptoms of schizophrenia be treated with an antidepressant or mood stabilizer only if the symptoms have not subsided after treatment of the psychosis with an atypical antipsychotic. Additionally, relative to older medications, atypicals have demonstrated benefit in improving some of the cognitive impairments.

AB - Recognition and treatment of schizophrenia has largely focused on positive symptoms of the disorder, such as delusions, hallucinations, and disorganization. However, other important symptoms, such as depression, cognition, and social functioning, have not received comparable attention. Fifty percent of schizophrenic patients suffer from comorbid depression, which is a major risk factor for suicide in this population, while 10% to 25% suffer from comorbid obsessive-compulsive disorder. Cognitive deficits commonly observed in patients with schizophrenia include problems with concentration, attention, and memory, as well as problem-solving and verbal skills. These deficits are observed at early stages of the illness and can predict deficits in functional capabilities, such as occupational and social skills, educational attainment, and the ability to live independently. The severity of such impairments affects all patients in this population, including up to 10% of patients working full time and up to one third of those working part time. In light of the debilitating effects of depression, cognitive impairment, and other aspects of affective functioning on the quality of life of patients with schizophrenia, physicians need to partner with their patients to address these concerns and determine an appropriate treatment regimen. This can be done with simple functional-based cognitive questioning, the use of evidence-based psychosocial practices, and psychoeducation on the many pharmacotherapeutic options. It is recommended that depressive or suicidal symptoms of schizophrenia be treated with an antidepressant or mood stabilizer only if the symptoms have not subsided after treatment of the psychosis with an atypical antipsychotic. Additionally, relative to older medications, atypicals have demonstrated benefit in improving some of the cognitive impairments.

UR - http://www.scopus.com/inward/record.url?scp=20644457934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20644457934&partnerID=8YFLogxK

U2 - 10.1017/S1092852900019337

DO - 10.1017/S1092852900019337

M3 - Article

C2 - 15803622

AN - SCOPUS:20644457934

VL - 10

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 2

ER -